Rucaparib Camsylate

芦卡帕利

Report date: 2026/02/24 20:00:16
NME

Base Information

Drug NameRucaparib Camsylate
Drug Alias Namerucaparib camsylate樟磺瑞卡帕布鲁卡帕尼RubracaAG-014699 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) Polymerase 3 inhibitorsPoly (ADP-Ribose) polymerase 1 inhibitorsPoly (ADP-Ribose) Polymerase 2 inhibitors
TargetsPoly (ADP-Ribose) Polymerase 2Poly (ADP-Ribose) Polymerase 3Poly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursDiabetes Mellitus +[28] 
Global Approved IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2016/12/19
Country/TerritoryCzechiaBelgiumCanada +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPfizer IncClovis Oncology Inc
China Registration ClassN/A

Develop Information

Active CompaniesGHN Pharma Nordic ABPharmaand GmbHClovis Oncology Inc +[6] 
Inactive CompaniesUtah State UniversityPfizer Inc
Active IndicationsSolid tumoursPeritoneal DiseasesProstatic Neoplasms, Castration-Resistant +[17] 
Inactive IndicationsMetastatic breast cancerDiabetes MellitusDiabetic Retinopathy +[11] 

Other Information

ATC CodeL01XX
Related LinksWikipediaDrugBankKEGG